What is PCI Biotech Holding ASA Book Value per Share?
PCI Biotech Holding ASA's book value per share for the quarter that ended in Dec. 2024 was kr0.63.
During the past 12 months, PCI Biotech Holding ASA's average Book Value Per Share Growth Rate was -40.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -40.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -39.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -0.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of PCI Biotech Holding ASA was 103.20% per year. The lowest was -53.90% per year. And the median was -26.65% per year.
During the past 13 years, the highest P/B Ratio of PCI Biotech Holding ASA was 2.39. The lowest was 0.00. And the median was 0.00.
PCI Biotech Holding ASA Book Value per Share Historical Data
The historical data trend for PCI Biotech Holding ASA's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
PCI Biotech Holding ASA Book Value per Share Chart
Competitive Comparison of PCI Biotech Holding ASA's Book Value per Share
For the Biotechnology subindustry, PCI Biotech Holding ASA's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PCI Biotech Holding ASA's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's PB Ratio distribution charts can be found below:
* The bar in red indicates where PCI Biotech Holding ASA's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
PCI Biotech Holding ASA (OSL:PCIB) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
PCI Biotech Holding ASA Book Value per Share Related Terms
Thank you for viewing the detailed overview of PCI Biotech Holding ASA's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSL:PCIB has been successfully added to your 